Move to topTop

TOKYO, JAPAN - February 4, 2020 - Terumo Corporation (TSE: 4543) today shared the latest information on its business operation and response in China, regarding the current outbreak of the novel coronavirus (2019-nCoV).

In China, Terumo currently has19 business locations (including 3 factories), in cities such as Beijing and Shanghai. As of February 4, there are no reports of Terumo Associates affected by the outbreak. To prevent further widespread and to protect the safety of associates, the company has requested associates to take prolonged vacation or to work from home. The Hong Kong and Taiwan office has resumed business from the end of January, and the factory in Hangzhou (Zhejiang Province) has resumed production from February 3; due to the healthcare company's social responsibility to provide resources needed to sustain basic medical care.

Also, Terumo has provided emergency relief supplies of 2,500 thermometers and 1,250 sphygmomanometers on February 2. The products were delivered by Terumo China Holdings to the two newly built hospitals in Wuhan (Huoshenshan Hospital and Leishenshan Hospital). Terumo also intends on providing extra-corporeal membrane oxygenation (ECMO) systems used for the treatment of severe pneumonia.

Based on its Group Mission of "Contributing to Society through Healthcare," Terumo will further strive to be of value to society at large.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.